Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Adrian Skelly"'
Publikováno v:
Vision, Vol 3, Iss 3, p 41 (2019)
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented. This ret
Externí odkaz:
https://doaj.org/article/487baa3f069b40fda6449169bba3e8ab
Autor:
Adrian Skelly, Nicholas Taylor, Christina Fasser, Jean-Pierre Malkowski, Pushpendra Goswami, Louise Downey
Publikováno v:
Advances in Therapy. 39:4808-4820
To identify patient preference drivers related to the management of wet age-related macular degeneration (wet AMD).In this cross-sectional study, a self-explicated 'conjoint analysis' survey was administered online to eligible patients with wet AMD (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06352a4a83ec9259c85ac0ed44feabdd
https://doi.org/10.1007/s12325-022-02248-5
https://doi.org/10.1007/s12325-022-02248-5
Autor:
Vladimir Bezlyak, Adrian Skelly, Laura Rodriguez Torres, Alexandros Sagkriotis, Arshad M. Khanani, Ray Griner
Publikováno v:
Ophthalmology Retina. 4:122-133
Purpose Characterize real-world baseline visual acuity (VA) and anti-vascular endothelial growth factor (VEGF) treatment patterns in neovascular age-related macular degeneration patients in 2012—2015. Design Retrospective, multicenter, nonintervent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d912660a792d54d3ff4294c74677cc
https://doi.org/10.1016/j.oret.2019.09.009
https://doi.org/10.1016/j.oret.2019.09.009
Autor:
Adrian Skelly, Nicholas Taylor, Christina Fasser, Jean-Pierre Malkowski, Pushpendra Goswami, Louise Downey
Publikováno v:
Advances in Therapy. 40:720-720
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a66285d06b0573ef1f46f653ce19f880
https://doi.org/10.1007/s12325-022-02381-1
https://doi.org/10.1007/s12325-022-02381-1
Publikováno v:
Journal of Comparative Effectiveness Research. 7:1125-1132
Aim: To determine the economic and humanistic burden of neovascular age-related macular degeneration (nAMD) in a cohort of patients treated with anti-VEGF in Europe and the US. Patients & methods: 79 respondents from the EU and 63 from the US with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eababd482a2032ce0a6b4a1b5f78a3
https://doi.org/10.2217/cer-2018-0058
https://doi.org/10.2217/cer-2018-0058
Autor:
Adrian Skelly, Julie Glanville, Ruth Pulikottil Jacob, Alberto Ferreira, Rachael McCool, Andriy Danyliv
Publikováno v:
Advances in Therapy
Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe: ranibizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c8941ee2965274a47bb008d5255b89e
https://doi.org/10.1007/s12325-017-0484-0
https://doi.org/10.1007/s12325-017-0484-0
Autor:
Paul Mitchell, Adrian Skelly, Alberto Ferreira, Robert L. Johnston, Hans-Joachim Carius, F Milnes
Publikováno v:
Advances in Therapy
Introduction Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1df9fb01cebbb206f56dd803daf49e
http://europepmc.org/articles/PMC5350206
http://europepmc.org/articles/PMC5350206
Publikováno v:
Vision
Volume 3
Issue 3
Vision, Vol 3, Iss 3, p 41 (2019)
Volume 3
Issue 3
Vision, Vol 3, Iss 3, p 41 (2019)
Treat and extend (T&
E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c807d77c629d58ed5f94207c11b1aa96
Autor:
F Milnes, Ray Griner, David S. Boyer, Alexandros Sagkriotis, Usha Chakravarthy, Vladimir Bezlyak, Adrian Skelly
Publikováno v:
Ophthalmology. Retina. 3(1)
Purpose To assess the long-term comparative effectiveness of ranibizumab versus switching to aflibercept in neovascular age-related macular degeneration (nAMD). Design A 24-month, retrospective, comparative, nonrandomized, matched cohort study. Parti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df64bf2f7b2ff02ce904691d71c517ca
https://pubmed.ncbi.nlm.nih.gov/30929819
https://pubmed.ncbi.nlm.nih.gov/30929819
Autor:
Andriy Danyliv, Julie Glanville, Rachael McCool, Alberto Ferreira, Adrian Skelly, Ruth Pulikottil Jacob
Publikováno v:
Advances in Therapy
Introduction Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Euro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1450f8c04714bcf7a0fb04202286d2a
https://pubmed.ncbi.nlm.nih.gov/28188433
https://pubmed.ncbi.nlm.nih.gov/28188433